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To Use Their Livers in The Era of Direct-Acting Antivirals?
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To the Editor:
We read with interest the report from the American Society of Transplantation Consensus Conference on the use of hepatitis C (HCV) viremic donors in solid organ transplantation, which took place in Dallas in January 2017 (1) .
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In the interferon-era, liver grafts from HCV-positive donors with no more than periportal fibrosis (F2 Ishak) did not show an outcome disadvantage compared with HCV-negative ones (2, 3) . In U.S., 16.9% of HCV-positive cirrhotics currently receive an organ from HCV-positive donors, 50% of whom are viremic and expected to transmit the infection (1) . Considering the gap between organ demand and supply, the meeting participants felt that the availability of safe and effective direct-acting antivirals (DAAs) makes expansion of the criteria for transplanting HCV viremic organs into non-viremic recipients a possibility (1) . However, no change was proposed to the current recommendations on accepting organs with higher fibrosis stages.
We recently reported the successful transplant of a liver with bridging fibrosis (F3 Ishak; Fig.1A 
8.5 kilopascal (kPa), and liver biopsy showed a chronic hepatitis with persistent bridging fibrosis (Ishak grade 4/18, stage 3/6).
We have closely followed up this patient and here we report his outcome at week 48 after therapy (72 weeks from LT). Viremia is persistently negative (SVR48); LS has decreased to 6.0 kPa; liver biopsy shows fibrous expansion of some portal areas without septation (Ishak grade 1/18, stage 1/6; Fig.1C,D) , in agreement with LS value; liver function tests are normal and Doppler-ultrasound shows normal liver echogenicity, regular biliary tree and blood perfusion with a spleen diameter reduced to 16 cm (from 20 cm at LT).
This report is a proof-of concept that treating HCV infection very early after LT with a pangenotypic DAA regimen, in carefully selected recipients, might allow not only to curb infection transmission into the recipient, but also to induce bridging fibrosis regression early after LT.
We submit that in the current DAA era, organs from HCV-viremic individuals represent an underutilized resource and prospective multicenter studies are urgently needed to evaluate not only transplantation of HCV viremic organs into non-viremic recipients, as discussed in Dallas, but also the criteria for acceptable graft fibrosis, provided that antiviral treatment is started very early post-LT.
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